These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31072919)

  • 21. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutrophil gelatinase-associated lipocalin as a biomarker of renal impairment in patients with multiple myeloma.
    Chae H; Ryu H; Cha K; Kim M; Kim Y; Min CK
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):35-40. PubMed ID: 25204517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
    Terpos E; Migkou M; Christoulas D; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Iakovaki M; Panagiotidis I; Ziogas DC; Fotiou D; Kastritis E; Dimopoulos MA
    Blood Cancer J; 2016 May; 6(5):e428. PubMed ID: 27232930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
    Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The value of serum free light chain in differential diagnosis of monoclonal gammopathy of renal significance].
    Li C; Wen YB; Li H; Su W; Li J; Cai JF; Chen LM; Li XM; Li XW
    Zhonghua Yi Xue Za Zhi; 2017 Aug; 97(30):2344-2348. PubMed ID: 28822451
    [No Abstract]   [Full Text] [Related]  

  • 26. The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets.
    Steiner N; Müller U; Hajek R; Sevcikova S; Borjan B; Jöhrer K; Göbel G; Pircher A; Gunsilius E
    PLoS One; 2018; 13(8):e0202045. PubMed ID: 30096165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic performances of M-protein tests according to the clinical presentations of kidney disease.
    Koo EH; Shin JH; Jang HR; Park HD; Kwon GY; Huh W; Kim DJ; Kim YG; Oh HY; Lee JE
    Eur J Intern Med; 2016 Sep; 33():88-92. PubMed ID: 27421913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloma progression and urinary gammaglobulin affect the urinary cystatin C to diagnose acute kidney injury in multiple myeloma.
    Kim JS; Yang JW; Park H; Kim YS; Lee JY; Lee JI; Han BG; Choi SO
    Clin Nephrol; 2014 May; 81(5):345-9. PubMed ID: 24780555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal tubular function and urinary N-acetyl-β-d-glucosaminidase and kidney injury molecule-1 levels in asthmatic children.
    Demir AD; Goknar N; Oktem F; Özkaya E; Yazıcı M; Torun E; Vehapoğlu A; Kucukkoc M
    Int J Immunopathol Pharmacol; 2016 Dec; 29(4):626-631. PubMed ID: 27272162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma and urinary cytokine homeostasis and renal dysfunction during cardiac surgery.
    Gormley SM; McBride WT; Armstrong MA; Young IS; McClean E; MacGowan SW; Campalani G; McMurray TJ
    Anesthesiology; 2000 Nov; 93(5):1210-6; discussion 5A. PubMed ID: 11046208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia.
    Voskaridou E; Terpos E; Michail S; Hantzi E; Anagnostopoulos A; Margeli A; Simirloglou D; Loukopoulos D; Papassotiriou I
    Kidney Int; 2006 Jun; 69(11):2037-42. PubMed ID: 16501491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
    Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
    Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCL18 promotes migration and invasion of multiple myeloma cells and is associated with poor prognosis.
    Qiao B; Chen L; Cheng Q; Wang G; Li Q; Zhang B; Li J; Hu Y; Sun C
    Carcinogenesis; 2023 May; 44(1):38-45. PubMed ID: 36455232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Presentation, Renal Histopathological Findings, and Outcome in Patients with Monoclonal Gammopathy and Kidney Disease.
    Alfano G; Delrio A; Fontana F; Mori G; Cazzato S; Ferrari A; Perrone R; Giovanella S; Ligabue G; Magistroni R; Cappelli G
    Int J Nephrol; 2021; 2021():8859340. PubMed ID: 34094600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implications.
    Corso A; Zappasodi P; Pascutto C; Bosoni T; Mangiacavalli S; Lorenzi A; Rusconi C; Lazzarino M
    Ann Hematol; 2003 Aug; 82(8):487-491. PubMed ID: 12838370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.